Tourmaline Bio (TRML) Stock Overview
Operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
TRML Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Tourmaline Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$18.23 |
| 52 Week High | US$29.79 |
| 52 Week Low | US$11.56 |
| Beta | 0 |
| 1 Month Change | 9.56% |
| 3 Month Change | 5.25% |
| 1 Year Change | 18.30% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 67.25% |
Recent News & Updates
Tourmaline Bio: TRANQUILITY Study Data Lends Credibility For IL-6 Inhibition
May 20We're Not Very Worried About Tourmaline Bio's (NASDAQ:TRML) Cash Burn Rate
Apr 19
Recent updates
Tourmaline Bio: TRANQUILITY Study Data Lends Credibility For IL-6 Inhibition
May 20We're Not Very Worried About Tourmaline Bio's (NASDAQ:TRML) Cash Burn Rate
Apr 19Tourmaline Bio: Looking To Go Beyond FcRn Inhibition With IL-6 Targeting
Oct 13Tourmaline Bio: Sinking On Rival's Stodgy Data - I'm Slightly Bearish
Mar 22Tourmaline Bio: Time For A Pause
Jan 18Shareholder Returns
| TRML | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -3.9% | -1.7% | 0.8% |
| 1Y | 18.3% | -13.2% | 13.7% |
Return vs Industry: TRML exceeded the US Biotechs industry which returned -11.9% over the past year.
Return vs Market: TRML exceeded the US Market which returned 14.8% over the past year.
Price Volatility
| TRML volatility | |
|---|---|
| TRML Average Weekly Movement | 7.9% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: TRML has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: TRML's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | 74 | Sandeep Kulkarni | www.tourmalinebio.com |
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company’s development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED).
Tourmaline Bio, Inc. Fundamentals Summary
| TRML fundamental statistics | |
|---|---|
| Market cap | US$474.72m |
| Earnings (TTM) | -US$82.87m |
| Revenue (TTM) | n/a |
Is TRML overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TRML income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$82.87m |
| Earnings | -US$82.87m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.23 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did TRML perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/21 13:15 |
| End of Day Share Price | 2025/07/21 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Tourmaline Bio, Inc. is covered by 12 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Konstantinos Biliouris | BMO Capital Markets Equity Research |
| Etzer Darout | BMO Capital Markets Equity Research |
| Joshua Schimmer | Cantor Fitzgerald & Co. |